nitrendipine has been researched along with Stroke in 15 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 9.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 5.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| " In secondary prevention, an additional risk reduction is modeled for eprosartan according to the results of the MOSES study ("Morbidity and Mortality after Stroke--Eprosartan Compared to Nitrendipine for Secondary Prevention")." | 3.75 | Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. ( Diener, HC; Gradl, B; Greiner, W; Jönsson, B; Lindgren, P; Lüders, S; Schrader, J; Schwander, B; Villar, FA; Zöllner, Y, 2009) |
| "Hypertension is the most important cardiovascular risk factor for stroke." | 2.43 | Effects of eprosartan on target organ protection. ( de la Sierra, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trenkwalder, P | 1 |
| Dowlatshahi, D | 1 |
| Hill, MD | 2 |
| Schwander, B | 1 |
| Gradl, B | 1 |
| Zöllner, Y | 1 |
| Lindgren, P | 1 |
| Diener, HC | 2 |
| Lüders, S | 2 |
| Schrader, J | 2 |
| Villar, FA | 1 |
| Greiner, W | 1 |
| Jönsson, B | 1 |
| Scholze, J | 1 |
| Thijs, L | 1 |
| Richart, T | 1 |
| de Leeuw, PW | 2 |
| Kuznetsova, T | 1 |
| Grodzicki, T | 1 |
| Kawecka-Jaszcz, K | 1 |
| O'Brien, E | 2 |
| Redón, J | 1 |
| Birkenhäger, WH | 2 |
| Fagard, R | 2 |
| Staessen, JA | 2 |
| Thijisq, L | 1 |
| Celis, H | 1 |
| Bulpitt, CJ | 1 |
| Fletcher, AE | 1 |
| Forette, F | 1 |
| Leonetti, G | 1 |
| McCormack, P | 1 |
| Nachev, C | 1 |
| Rodicio, JL | 1 |
| Rosenfeld, J | 1 |
| Sarti, C | 1 |
| Tuomilehto, J | 1 |
| Webster, J | 1 |
| Yodfat, Y | 1 |
| Zanchetti, A | 1 |
| Kulschewski, A | 1 |
| Hammersen, F | 1 |
| Plate, K | 1 |
| Berger, J | 1 |
| Zidek, W | 1 |
| Dominiak, P | 1 |
| Bloch, MJ | 1 |
| Basile, J | 1 |
| Boulanger, JM | 1 |
| Strauss, MH | 1 |
| Verma, S | 1 |
| Owen, A | 1 |
| Larsen, K | 1 |
| Hornnes, N | 1 |
| Boysen, G | 1 |
| Johnston, SC | 1 |
| de la Sierra, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stroke Prediction Study Using a Model Based on Internet Search Queries[NCT04755959] | 450 participants (Anticipated) | Observational | 2021-02-28 | Not yet recruiting | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nitrendipine and Stroke
| Article | Year |
|---|---|
Effects of eprosartan on target organ protection.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure | 2006 |
5 trials available for nitrendipine and Stroke
| Article | Year |
|---|---|
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Dihydrop | 2004 |
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; B | 2005 |
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, S | 2006 |
MOSES raises questions.
Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Stati | 2006 |
MOSES: superiority or noninferiority?
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2006 |
9 other studies available for nitrendipine and Stroke
| Article | Year |
|---|---|
[Combined drug therapy is better: successfully protecting elderly hypertensive patients].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combina | 2008 |
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2009 |
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Topics: Acrylates; Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Enalapril; Europ | 2009 |
[Isolated systolic hypertension].
Topics: Age Factors; Aged, 80 and over; Antihypertensive Agents; Drug Combinations; Enalapril; Female; Human | 2009 |
Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug T | 2010 |
Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Humans; Hypertension; | 2005 |
Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocker | 2006 |
Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocker | 2006 |
[Not all antihypertensive agents protect equally well].
Topics: Acrylates; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |